骨髄異形成症候群治療薬の世界市場レポート 2025年

骨髄異形成症候群治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.7％で35億8,000万米ドルに成長します。予測期間の成長は、高齢者人口の増加、標的治療の進歩、疾患メカニズムの理解の深まり、認知度の向上と早期診断、腫瘍学研究の拡大に起因すると考えられます。予測期間における主な動向としては、赤血球造血刺激因子製剤の最適化、併用療法、鉄キレート療法への注目の高まり、規制当局の承認と市場参入、患者中心のケアモデルなどが挙げられます。

骨髄異形成症候群の患者数の増加が予想されることから、この疾患を治療する薬剤の市場成長が見込まれます。骨髄異形成症候群は、骨髄における血球の発達に影響を及ぼす疾患群で、血液がんの一種に分類されます。この症候群の治療薬は免疫系を調節し、赤血球輸血の必要性を減らすことを目的としています。特に、2022年10月にAmerican Journal of Managed Careが発表した推計によると、米国における骨髄異形成症候群の有病率は60,000～175,000例であり、罹患率の増加による市場の成長を裏付けています。

個別化医療に対する需要の急増は、骨髄異形成症候群治療薬市場拡大の原動力になると予想されます。個別化医療は、個人固有の遺伝的・医学的特性に基づいて治療をカスタマイズするものです。このアプローチは治療結果を最適化し、副作用を最小化するもので、特に骨髄異形成症候群の異質な性質を管理するのに適しています。注目すべきは、2022年にFDAの医薬品評価研究センターが37の新規分子実体を認可したことで、個別化医療連合は12（約34％）を個別化医療に分類し、市場の成長軌道を強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界骨髄異形成症候群治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の骨髄異形成症候群治療薬市場：成長率分析
• 世界の骨髄異形成症候群治療薬市場の実績：規模と成長, 2019-2024
• 世界の骨髄異形成症候群治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界骨髄異形成症候群治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の骨髄異形成症候群治療薬市場治療クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫調節薬
• 低メチル化剤
• 抗貧血薬
• 世界の骨髄異形成症候群治療薬市場症候群の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多系統異形成を伴う難治性血球減少症（RCMD）
• 不応性貧血（RA）
• 芽球過剰を伴う不応性貧血（RAEB）
• 環状鉄芽球性難治性貧血（RARS）
• 世界の骨髄異形成症候群治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界の骨髄異形成症候群治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オリジナル
• ジェネリック
• 世界の骨髄異形成症候群治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 外来手術センター
• 世界の骨髄異形成症候群治療薬市場、免疫調節薬のサブセグメンテーション、治療クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• サリドマイド
• レナリドミド
• ポマリドミド
• 世界の骨髄異形成症候群治療薬市場、治療クラスによる低メチル化剤のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アザシチジン
• デシタビン
• グアデシタビン
• 世界の骨髄異形成症候群治療薬市場抗貧血薬のサブセグメンテーション、治療クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 赤血球造血刺激因子（ESA）
• 鉄サプリメント
• 輸血用製品

第7章 地域別・国別分析

• 世界の骨髄異形成症候群治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の骨髄異形成症候群治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 骨髄異形成症候群治療薬市場：競合情勢
• 骨髄異形成症候群治療薬市場：企業プロファイル
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Cipla Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Dr. Reddy's Laboratories Ltd.
• Lupin Ltd.
• Onconova Therapeutics Inc.
• Sun Pharmaceutical Industries Limited
• FibroGen Inc.
• Aprea Therapeutics
• Bayer AG
• Bristol Myers Squibb
• Celator Pharmaceuticals
• Crystal Genomics Inc.
• AbbVie Inc.
• Astex Pharmaceuticals Inc.
• Geron Co.
• Hikma Pharmaceuticals plc
• Jazz Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 骨髄異形成症候群治療薬市場2029：新たな機会を提供する国
• 骨髄異形成症候群治療薬市場2029：新たな機会を提供するセグメント
• 骨髄異形成症候群治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Myelodysplastic syndrome (MDS) covers a spectrum of conditions where the bone marrow struggles to produce enough healthy blood cells-red blood cells, white blood cells, and platelets due to irregular cell formation and maturation. This deficiency arises from uncontrolled cell growth and division, causing tissue damage. Medications for myelodysplastic syndrome encompass epoetin alfa, darbepoetin alfa, filgrastim, and other drugs tailored for MDS treatment.

The primary types of drug therapies for myelodysplastic syndrome fall into three categories immunomodulatory drugs, hypomethylating agents, and anti-anemics. Immunomodulatory drugs (IMiDs) constitute a medication class that adjusts or regulates the immune system's response while directly impacting bone marrow cells. The spectrum of syndromes includes refractory cytopenia with multilineage dysplasia, refractory anemia, refractory anemia with excess blasts, and refractory anemia with ringed sideroblasts. These drugs can be administered through various routes such as oral and parenteral methods and serve multiple applications, including original and generic treatments. They are utilized by various end-users, including hospitals, clinics, and ambulatory surgical centers, to address the diverse needs of individuals diagnosed with MDS.

The myelodysplastic syndrome drugs market research report is one of a series of new reports from The Business Research Company that provides myelodysplastic syndrome drugs market statistics, including myelodysplastic syndrome drugs industry global market size, regional shares, competitors with a myelodysplastic syndrome drugs market share, detailed myelodysplastic syndrome drugs market segments, market trends and opportunities, and any further data you may need to thrive in the myelodysplastic syndrome drugs industry. This myelodysplastic syndrome drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myelodysplastic syndrome drugs market size has grown strongly in recent years. It will grow from$2.25 billion in 2024 to $2.47 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to aging population, advancements in diagnostics, chemotherapy-related MDS cases, increased cancer survivors, clinical research and drug development

The myelodysplastic syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $3.58 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to growing geriatric population, advancements in targeted therapies, increased understanding of disease mechanisms, rising awareness and early diagnosis, expansion of oncology research. Major trends in the forecast period include erythropoiesis-stimulating agents optimization, combination therapies, increasing focus on iron chelation therapy, regulatory approvals and market access, patient-centric care models.

The anticipated rise in myelodysplastic syndrome cases is set to drive growth in the market for drugs treating this condition. Myelodysplastic syndrome represents a group of disorders impacting blood cell development in the bone marrow, categorized as a form of blood cancer. Medications for this syndrome aim to modulate the immune system, reducing the need for red blood cell transfusions. Notably, estimates from the American Journal of Managed Care in October 2022 place the prevalence of myelodysplastic syndrome in the USA between 60,000 to 175,000 cases, substantiating the market's growth due to increased incidences.

The burgeoning demand for personalized medicine is expected to be a driving force behind the expansion of the myelodysplastic syndrome drugs market. Personalized medicine involves tailoring treatments based on an individual's unique genetic and medical characteristics. This approach optimizes treatment outcomes and minimizes adverse effects, especially relevant in managing the heterogeneous nature of myelodysplastic syndrome. Notably, in 2022, the FDA's Center for Drug Evaluation and Research greenlit 37 new molecular entities, with the Personalized Medicine Coalition categorizing 12, around 34%, as personalized medicines, emphasizing the market's growth trajectory.

Leading companies in the myelodysplastic syndrome drugs market are focusing on developing telomerase inhibitors to target the enzyme telomerase, with the aim of slowing disease progression by limiting the uncontrolled division of abnormal cells. These inhibitors are beneficial in treating myelodysplastic syndrome as they function by inhibiting telomerase, which can reduce the proliferation of abnormal cells and potentially enhance patient outcomes. For example, in June 2024, Geron Corporation, a biotechnology firm based in the U.S., launched Rytelo (imetelstat), an FDA-approved intravenous telomerase inhibitor designed for adults with low to intermediate-1 risk myelodysplastic syndromes (LR-MDS) and transfusion-dependent anemia that is unresponsive to and ineligible for erythropoiesis-stimulating agents (ESA). Rytelo provides durable transfusion independence, improves hemoglobin levels, and addresses a significant unmet need in the myelodysplastic syndrome drugs market while maintaining a manageable safety profile.

Prominent companies operating in the myelodysplastic syndrome drugs sector are intensifying efforts to introduce novel medications, aiming to gain a competitive edge. TIBSOVO, an oral targeted therapy inhibiting the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, is a prime example. Approved for treating adult patients with relapsed or refractory myelodysplastic syndromes (MDS), TIBSOVO represents a significant milestone in the industry. Notably, Servier Laboratories' approval of TIBSOVO by the US FDA in October 2023 marks the first targeted therapy sanctioned for this indication. The approval stems from a pivotal Phase I study evaluating its efficacy in this new application.

In January 2023, Merck, a pharmaceutical company based in the U.S., acquired Imago Biosciences, Inc. for an undisclosed amount. This acquisition is intended to strengthen Merck's hematology capabilities by incorporating Imago Biosciences' innovative therapies. Imago Biosciences, Inc. specializes in the development of cutting-edge therapies for hematologic malignancies, including myelodysplastic syndromes (MDS).

Major companies operating in the myelodysplastic syndrome drugs market include Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, Crystal Genomics Inc., AbbVie Inc., Astex Pharmaceuticals Inc., Geron Co., Hikma Pharmaceuticals plc, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Syros Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Agios Pharmaceuticals Inc., Incyte Corporation, Array Biopharma Inc., MEI Pharma Inc.

North America was the largest region in the Myelodysplastic syndrome drugs market in 2024. Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the myelodysplastic syndrome drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The myelodysplastic syndrome drug market consists of sales of drugs such as azacytidine, decitabine, and lenalidomide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myelodysplastic Syndrome Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myelodysplastic syndrome drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myelodysplastic syndrome drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myelodysplastic syndrome drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutic Class: Immunomodulatory Drugs; Hypomethylating Agents; Anti-anemics
• 2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts
• 3) By Route of Administration: Oral; Parenteral
• 4) By Applications: Original; Generics
• 5) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers
• Subsegments:
• 1) By Immunomodulatory Drugs: Thalidomide; Lenalidomide; Pomalidomide
• 2) By Hypomethylating Agents: Azacitidine; Decitabine; Guadecitabine
• 3) By Anti-anemics: Erythropoiesis-Stimulating Agents (ESAs); Iron Supplements; Blood Transfusion Products
• Companies Mentioned: Amgen Inc.; Celgene Corporation; Otsuka Pharmaceutical Co. Ltd.; Takeda Pharmaceutical Company Limited; Cipla Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Myelodysplastic Syndrome Drugs Market Characteristics

3. Myelodysplastic Syndrome Drugs Market Trends And Strategies

4. Myelodysplastic Syndrome Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Myelodysplastic Syndrome Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Myelodysplastic Syndrome Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Myelodysplastic Syndrome Drugs Market Growth Rate Analysis
• 5.4. Global Myelodysplastic Syndrome Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Myelodysplastic Syndrome Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Myelodysplastic Syndrome Drugs Total Addressable Market (TAM)

6. Myelodysplastic Syndrome Drugs Market Segmentation

• 6.1. Global Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunomodulatory Drugs
• Hypomethylating Agents
• Anti-anemics
• 6.2. Global Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Refractory Cytopenia With Multilineage Dysplasia (RCMD)
• Refractory Anemia (RA)
• Refractory Anemia With Excess Blasts (RAEB)
• Refractory Anemia With Ringed Sideroblasts (RARS)
• 6.3. Global Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Myelodysplastic Syndrome Drugs Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Original
• Generics
• 6.5. Global Myelodysplastic Syndrome Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• 6.6. Global Myelodysplastic Syndrome Drugs Market, Sub-Segmentation Of Immunomodulatory Drugs, By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thalidomide
• Lenalidomide
• Pomalidomide
• 6.7. Global Myelodysplastic Syndrome Drugs Market, Sub-Segmentation Of Hypomethylating Agents, By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Azacitidine
• Decitabine
• Guadecitabine
• 6.8. Global Myelodysplastic Syndrome Drugs Market, Sub-Segmentation Of Anti-anemics, By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erythropoiesis-Stimulating Agents (ESAs)
• Iron Supplements
• Blood Transfusion Products

7. Myelodysplastic Syndrome Drugs Market Regional And Country Analysis

• 7.1. Global Myelodysplastic Syndrome Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Myelodysplastic Syndrome Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myelodysplastic Syndrome Drugs Market

• 8.1. Asia-Pacific Myelodysplastic Syndrome Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myelodysplastic Syndrome Drugs Market

• 9.1. China Myelodysplastic Syndrome Drugs Market Overview
• 9.2. China Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myelodysplastic Syndrome Drugs Market

• 10.1. India Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myelodysplastic Syndrome Drugs Market

• 11.1. Japan Myelodysplastic Syndrome Drugs Market Overview
• 11.2. Japan Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myelodysplastic Syndrome Drugs Market

• 12.1. Australia Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myelodysplastic Syndrome Drugs Market

• 13.1. Indonesia Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myelodysplastic Syndrome Drugs Market

• 14.1. South Korea Myelodysplastic Syndrome Drugs Market Overview
• 14.2. South Korea Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myelodysplastic Syndrome Drugs Market

• 15.1. Western Europe Myelodysplastic Syndrome Drugs Market Overview
• 15.2. Western Europe Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myelodysplastic Syndrome Drugs Market

• 16.1. UK Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myelodysplastic Syndrome Drugs Market

• 17.1. Germany Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myelodysplastic Syndrome Drugs Market

• 18.1. France Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myelodysplastic Syndrome Drugs Market

• 19.1. Italy Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myelodysplastic Syndrome Drugs Market

• 20.1. Spain Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myelodysplastic Syndrome Drugs Market

• 21.1. Eastern Europe Myelodysplastic Syndrome Drugs Market Overview
• 21.2. Eastern Europe Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myelodysplastic Syndrome Drugs Market

• 22.1. Russia Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myelodysplastic Syndrome Drugs Market

• 23.1. North America Myelodysplastic Syndrome Drugs Market Overview
• 23.2. North America Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myelodysplastic Syndrome Drugs Market

• 24.1. USA Myelodysplastic Syndrome Drugs Market Overview
• 24.2. USA Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myelodysplastic Syndrome Drugs Market

• 25.1. Canada Myelodysplastic Syndrome Drugs Market Overview
• 25.2. Canada Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myelodysplastic Syndrome Drugs Market

• 26.1. South America Myelodysplastic Syndrome Drugs Market Overview
• 26.2. South America Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myelodysplastic Syndrome Drugs Market

• 27.1. Brazil Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myelodysplastic Syndrome Drugs Market

• 28.1. Middle East Myelodysplastic Syndrome Drugs Market Overview
• 28.2. Middle East Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myelodysplastic Syndrome Drugs Market

• 29.1. Africa Myelodysplastic Syndrome Drugs Market Overview
• 29.2. Africa Myelodysplastic Syndrome Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Myelodysplastic Syndrome Drugs Market, Segmentation By Type of Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Myelodysplastic Syndrome Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myelodysplastic Syndrome Drugs Market Competitive Landscape And Company Profiles

• 30.1. Myelodysplastic Syndrome Drugs Market Competitive Landscape
• 30.2. Myelodysplastic Syndrome Drugs Market Company Profiles
  • 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Cipla Limited Overview, Products and Services, Strategy and Financial Analysis

31. Myelodysplastic Syndrome Drugs Market Other Major And Innovative Companies

• 31.1. Dr. Reddy's Laboratories Ltd.
• 31.2. Lupin Ltd.
• 31.3. Onconova Therapeutics Inc.
• 31.4. Sun Pharmaceutical Industries Limited
• 31.5. FibroGen Inc.
• 31.6. Aprea Therapeutics
• 31.7. Bayer AG
• 31.8. Bristol Myers Squibb
• 31.9. Celator Pharmaceuticals
• 31.10. Crystal Genomics Inc.
• 31.11. AbbVie Inc.
• 31.12. Astex Pharmaceuticals Inc.
• 31.13. Geron Co.
• 31.14. Hikma Pharmaceuticals plc
• 31.15. Jazz Pharmaceuticals Inc.

32. Global Myelodysplastic Syndrome Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myelodysplastic Syndrome Drugs Market

34. Recent Developments In The Myelodysplastic Syndrome Drugs Market

35. Myelodysplastic Syndrome Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Myelodysplastic Syndrome Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Myelodysplastic Syndrome Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Myelodysplastic Syndrome Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer